Biontech Se Sponsored Adr (BNTX) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioNTech SE (BNTX) has completed an epidemiological study called “Epidemiological Study to Determine the Prevalence of ctDNA Positivity in Participants With Stage II (High Risk) or Stage III CRC After Surgery With Curative (R0) Intent and Subsequent Adjuvant Chemotherapy With Monitoring of ctDNA During Clinical Follow-up.” The study tracks patients with resected colorectal cancer using blood tests to spot lingering cancer signals, aiming to guide who might benefit from later experimental treatment.
The intervention in this study is not a drug but a procedure. Patients give regular blood samples for circulating tumor DNA, or ctDNA, so BioNTech can see how often these cancer traces appear and how they change over time after surgery and chemotherapy.
The study is observational, not a randomized drug trial. All eligible patients are followed in a single cohort, with prospective monitoring and no masking, to understand how ctDNA status links to disease course and to identify candidates for follow-on trials.
The trial was first submitted on 2021-03-17, marking the official launch of this data-gathering effort. The most recent update was filed on 2026-05-21, and the overall status is listed as completed, signaling that follow-up is done and the focus now shifts to analysis and use of the data.
For investors, this study supports BioNTech’s push beyond vaccines into oncology and precision medicine, using ctDNA to select patients for its BNT122-01 program and similar assets. Positive use of these data could bolster confidence in BNTX’s cancer pipeline, while also putting pressure on rivals in the liquid biopsy and oncology segments to show equally strong patient-selection strategies.
The study has been completed and recently updated in the ClinicalTrials system, and further details are available on the ClinicalTrials portal.
To learn more about BNTX’s potential, visit the Biontech Se Sponsored Adr drug pipeline page.